Daily Cardiology Research Analysis
Analyzed 164 papers and selected 3 impactful papers.
Summary
Analyzed 164 papers and selected 3 impactful articles.
Selected Articles
1. Proteogenomics of Hypertrophic Cardiomyopathy Reveals Subtype-Specific Therapy.
Integrated multi-omics of 132 HCM hearts identified two proteome-based subtypes (severe and mild) with 550 signature proteins, where the severe subtype predominantly drove reductions in fatty acid oxidation and oxidative phosphorylation. Genetic evidence linked reduced fatty acid oxidation causally to HCM. Baicalin, predicted to augment fatty acid oxidation, improved metabolic and hypertrophic phenotypes in severe-subtype iPSC-derived cardiomyocytes and in vivo.
Impact: This work delineates metabolic heterogeneity in HCM with causal support and translates it into a subtype-specific therapeutic candidate, advancing precision cardiomyopathy care.
Clinical Implications: While not practice-changing yet, the study supports metabolic risk stratification and suggests fatty acid oxidation augmentation (e.g., baicalin) as a potential therapy for a severe HCM subtype. It motivates profiling-based trial designs and tailored therapy.
Key Findings
- Unsupervised proteogenomic clustering of 132 HCM myocardium samples identified two molecular subtypes (severe and mild) defined by 550 signature proteins.
- Reductions in fatty acid oxidation and oxidative phosphorylation versus controls were predominantly driven by the severe subtype and associated with worse clinical phenotype.
- Genetic analyses supported a causal link between reduced fatty acid oxidation and HCM pathogenesis.
- Baicalin, predicted in silico to facilitate fatty acid oxidation, improved metabolic and hypertrophic phenotypes in severe-subtype iPSC-cardiomyocytes and in vivo models.
Methodological Strengths
- Integrated multi-omics (WES, RNA-seq, proteomics) with unsupervised clustering and external validation cohorts
- Translational loop from subtype discovery to in silico drug nomination and in vitro/in vivo functional testing
Limitations
- Single-disease cohort with modest sample size; generalizability across ancestries and genotypes requires validation
- Baicalin efficacy remains preclinical; dosing, safety, and target engagement in humans are unknown
Future Directions: Prospective trials using proteotype-guided stratification; mechanistic dissection of FAO deficits; clinical development of FAO-enhancing strategies including baicalin with pharmacodynamic biomarkers.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a heterogeneous disease with diverse prognosis. The underlying mechanisms remain unknown, resulting in limited risk stratification and therapeutic strategies. This study aimed to elucidate molecular subtypes of HCM through integrated proteogenomic analysis and explore subtype-specific therapeutic strategies. METHODS: We conducted an integrated proteogenomic analysis of 132 patients with HCM using myocardial samples, incorporating whole-exome sequencing, RNA sequencing, and proteomics. Unsupervised clustering w
2. Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial.
In 1,800 diabetics with multivessel CAD, an ultra–thin biodegradable polymer sirolimus-eluting stent was noninferior to a durable polymer everolimus-eluting stent for 1-year target lesion failure (7.92% vs 8.75%). A 2×2 factorial design also randomized P2Y12 therapy (ticagrelor vs prasugrel). Findings support device interchangeability under contemporary optimal medical therapy in this high-risk group.
Impact: A large, prospective, randomized comparison focused on diabetic multivessel disease—often underrepresented—provides high-quality evidence to guide stent selection.
Clinical Implications: Both platforms are reasonable options for diabetics with multivessel CAD receiving optimal medical therapy. Decisions may prioritize lesion complexity, deliverability, and operator experience rather than presumed efficacy gaps.
Key Findings
- Primary endpoint (1-year target lesion failure) was 7.92% with ultra–thin BP-SES vs 8.75% with DP-EES; prespecified noninferiority criterion was met.
- Investigator-initiated, multicenter, prospective, open-label, 2×2 factorial randomized design (stent type and P2Y12 inhibitor).
- Trial enrolled exclusively patients with diabetes and multivessel disease, a high-risk population often excluded from head-to-head device trials.
Methodological Strengths
- Large randomized multicenter factorial design with prespecified noninferiority margin
- High-risk diabetic multivessel cohort enhances external validity for a key clinical subgroup
Limitations
- Open-label design and 1-year follow-up limit detection of very late events and subtle performance differences
- Results pertain to specific stent platforms; generalization to other devices requires caution
Future Directions: Longer-term follow-up for late events (ST, neoatherosclerosis) in diabetics; subgroup analyses by lesion complexity and small vessels; head-to-heads incorporating physiology- and imaging-guided PCI strategies.
BACKGROUND: Patients with diabetes frequently have multivessel disease and are at increased risk of adverse outcomes. The outcomes with a new-generation ultra-thin strut sirolimus-eluting stent (SES) vs everolimus-eluting stent (EES) is unclear as stent-to-stent comparison trials have routinely excluded these patients or included a small proportion of such patients. OBJECTIVES: The purpose of this study was to compare the clinical outcomes of ultra-thin biodegradable polymer (BP) SES vs durable polymer (DP) EES when combined with contemporary optimal medical therapy in patients with diabetes and multivessel disease. METHODS: The TUXEDO-2 is an investigator-initiated prospective, open-label, multicenter, 2 × 2 factorial, randomized (1:1) controlled trial. Patients undergoing percutaneous coronary intervention were randomized to receive either a Supraflex Cruz SES or Xience EES. The participants were also randomized to Ticagrelor or Prasugrel. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction or ischemia-driven target lesion revascularization at 1-year follow up. The trial was designed to test noninferiority of BP-SES vs DP-EES, with a noninferiority margin of 4.5% (1-sided upper 97.5% confidence bound). RESULTS: Among the 1,800 patients randomized, mean age was 60.3 years with 28% of participants being women. At 1 year, the primary endpoint of target lesion failure occurred in 148 patients, including 70 patients (7.92%) in the BP-SES group and 78 patients (8.75%) in the DP-EES group. The risk difference of -0.83 percentage points (1-sided upper 97.5% confidence bound 3.42%) met the prespecified noninferiority margin (P CONCLUSIONS: In patients with diabetes and multivessel disease undergoing percutaneous coronary intervention, ultra-thin biodegradable polymer SES was noninferior to durable polymer EES at 1 year follow-up. (Trial Registration Number CTRI/2019/11/022088).
3. Variability in Cardiac Stress Test Interpretation: Agreement Between Enrollment Sites and Core Laboratories in the Global ISCHEMIA Trial.
Across 6,971 ISCHEMIA participants, site stress test interpretations frequently diverged from blinded core laboratory adjudication, with only ~55% agreement and ~25% of site moderate/severe cases downgraded to none/mild by core labs. Overestimation odds were elevated across modalities. These data expose substantial interpretive variability that can affect patient selection and management.
Impact: Shows that routine stress test interpretation can be inconsistent even within a landmark trial, motivating standardization, training, and potential AI-assisted adjudication.
Clinical Implications: Referral and treatment decisions should consider potential overestimation of ischemia by site reads. Adopting standardized protocols, core-lab style criteria, and decision support may reduce misclassification and unnecessary invasive procedures.
Key Findings
- Median site–core lab agreement for ischemia severity was ~55% across modalities; about 25% of site moderate/severe cases were downgraded to none/mild by core labs.
- Adjusted median odds ratios for site overestimation: nuclear 2.36, echocardiography 1.98, CMR 1.89, exercise test 2.15; underestimation ORs 1.25–1.77.
- Core labs reclassified site determinations to 8% none, 11% mild, 30% moderate, and 51% severe ischemia.
Methodological Strengths
- Blinded central core-lab reinterpretation used as reference across multiple imaging modalities
- Robust mixed-effects modeling with random site intercepts in a large global RCT framework
Limitations
- Analysis focused on baseline qualifying tests; not linked to downstream clinical outcomes in this report
- Site selection biases and modality availability may influence generalizability
Future Directions: Develop modality-specific standardized interpretation frameworks, training, and QA; evaluate AI-assisted adjudication; link reclassification to outcomes and cost-effectiveness.
BACKGROUND: Cardiac stress testing is a cornerstone of risk stratification and management in patients with chronic coronary disease, yet the consistency and accuracy of its interpretation remain poorly defined. This analysis evaluated variation in the interpretation of myocardial ischemia between enrollment sites and core laboratories in the ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches). METHODS: ISCHEMIA was a global (37 countries, 2012-2018) randomized trial of an initial invasive versus conservative strategy in patients with chronic coronary disease and moderate or severe ischemia. This analysis included participants with site-interpreted qualifying stress tests-nuclear, echocardiography (echo), cardiac magnetic resonance, or exercise tolerance test-and independent core laboratory adjudication. Core laboratories, serving as the reference standard, reinterpreted tests blinded to site results. A trinary outcome variable (site underestimation, concordance, or overestimation) was defined by comparing site-determined ischemia levels to standardized core lab assessments. Adjusted mixed-effects logistic regression models with random site intercepts assessed variability. RESULTS: Among 6971 participants (mean age, 62.8 years; 73% men), site interpretations showed 0% no/mild (by design), 43% moderate, and 57% severe ischemia. Core labs reclassified these as 8% none, 11% mild, 30% moderate, and 51% severe ischemia. For the imaging modalities, median site-core lab agreement rates were ≈55%; nearly 25% of site-classified moderate/severe cases were downgraded to no or mild ischemia by core labs. Adjusted median odds ratios for site overestimation were 2.36 (95% CI, 2.02-2.82; nuclear), 1.98 (95% CI, 1.62-2.60; echo), 1.89 (95% CI, 1.0-5.41; cardiac magnetic resonance), and 2.15 (95% CI, 1.76-2.79; exercise tolerance test). Adjusted median odds ratios for underestimation ranged from 1.25 to 1.77. CONCLUSIONS: In ISCHEMIA, enrollment sites frequently overestimated or underestimated the severity of myocardial ischemia compared with core laboratory assessments, highlighting the need for strategies to improve the consistency and accuracy of stress testing interpretation in patients with chronic coronary disease. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01471522.